Quest Diagnostics Common Stock Net 2010-2024 | DGX

Quest Diagnostics common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
  • Quest Diagnostics common stock net for the quarter ending December 31, 2024 was $0.002B, a 0% increase year-over-year.
  • Quest Diagnostics common stock net for 2024 was $0.002B, a 0% decline from 2023.
  • Quest Diagnostics common stock net for 2023 was $0.002B, a 0% decline from 2022.
  • Quest Diagnostics common stock net for 2022 was $0.002B, a 0% decline from 2021.
Quest Diagnostics Annual Common Stock Net
(Millions of US $)
2024 $2
2023 $2
2022 $2
2021 $2
2020 $2
2019 $2
2018 $2
2017 $2
2016 $2
2015 $2
2014 $2
2013 $2
2012 $2
2011 $2
2010 $2
2009 $2
Quest Diagnostics Quarterly Common Stock Net
(Millions of US $)
2024-12-31 $2
2024-09-30 $2
2024-06-30 $2
2024-03-31 $2
2023-12-31 $2
2023-09-30 $2
2023-06-30 $2
2023-03-31 $2
2022-12-31 $2
2022-09-30 $2
2022-06-30 $2
2022-03-31 $2
2021-12-31 $2
2021-09-30 $2
2021-06-30 $2
2021-03-31 $2
2020-12-31 $2
2020-09-30 $2
2020-06-30 $2
2020-03-31 $2
2019-12-31 $2
2019-09-30 $2
2019-06-30 $2
2019-03-31 $2
2018-12-31 $2
2018-09-30 $2
2018-06-30 $2
2018-03-31 $2
2017-12-31 $2
2017-09-30 $2
2017-06-30 $2
2017-03-31 $2
2016-12-31 $2
2016-09-30 $2
2016-06-30 $2
2016-03-31 $2
2015-12-31 $2
2015-09-30 $2
2015-06-30 $2
2015-03-31 $2
2014-12-31 $2
2014-09-30 $2
2014-06-30 $2
2014-03-31 $2
2013-12-31 $2
2013-09-30 $2
2013-06-30 $2
2013-03-31 $2
2012-12-31 $2
2012-09-30 $2
2012-06-30 $2
2012-03-31 $2
2011-12-31 $2
2011-09-30 $2
2011-06-30 $2
2011-03-31 $2
2010-12-31 $2
2010-09-30 $2
2010-06-30 $2
2010-03-31 $2
2009-12-31 $2
2009-09-30 $2
2009-06-30 $2
2009-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $19.317B $9.872B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $21.804B 0.00
DaVita (DVA) United States $11.363B 14.49
Encompass Health (EHC) United States $9.962B 22.32
Chemed (CHE) United States $8.236B 25.31
Elanco Animal Health (ELAN) United States $5.492B 13.07
Option Care Health (OPCH) United States $5.459B 25.87
RadNet (RDNT) United States $4.453B 98.62
Amedisys (AMED) United States $2.998B 21.34
LifeStance Health (LFST) United States $2.904B 0.00
Addus HomeCare (ADUS) United States $1.974B 22.91
Astrana Health (ASTH) United States $1.946B 26.61
U.S Physical Therapy (USPH) United States $1.298B 34.13
Pennant (PNTG) United States $0.864B 34.93
Aveanna Healthcare Holdings (AVAH) United States $0.799B 0.00
Atai Life Sciences (ATAI) Germany $0.305B 0.00
Bioqual (BIOQ) United States $0.054B 0.00
Daxor (DXR) United States $0.036B 0.00
Ontrak (OTRK) United States $0.007B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00
Psychemedics (PMD) United States $0.000B 0.00